Research programme: spinal cord injury therapies - AnaMar
Alternative Names: AM 250; Project AM 250 - SCILatest Information Update: 04 Nov 2017
At a glance
- Originator AnaMar Medical
- Class Small molecules
- Mechanism of Action Melanocortin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Spinal cord injuries
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-cord-injuries in Sweden
- 25 Jul 2008 Preclinical development is ongoing
- 25 Jul 2006 Preclinical trials in Spinal cord injuries in Sweden (unspecified route)